Novel methylation markers of the dysexecutive-psychiatric phenotype in FMR1 premutation women

Objective: To examine the epigenetic basis of psychiatric symptoms and dysexecutive impairments in FMR1 premutation (PM: 55 to 199 CGG repeats) women. Methods: A total of 35 FMR1 PM women aged between 22 and 55 years and 35 age- and IQ-matched women controls (CGG <45) participated in this study. All participants completed a range of executive function tests and self-reported symptoms of psychiatric disorders. The molecular measures included DNA methylation of the FMR1 CpG island in blood, presented as FMR1 activation ratio (AR), and 9 CpG sites located at the FMR1 exon1/intron 1 boundary, CGG size, and FMR1 mRNA levels. Results: We show that FMR1 intron 1 methylation levels could be used to dichotomize PM women into greater and lower risk categories (p = 0.006 to 0.037; odds ratio = 14–24.8), with only FMR1 intron 1 methylation, and to a lesser extent AR, being significantly correlated with the likelihood of probable dysexecutive or psychiatric symptoms (p < 0.05). Furthermore, the significant relationships between methylation and social anxiety were found to be mediated by executive function performance, but only in PM women. FMR1 exon 1 methylation, CGG size, and FMR1 mRNA could not predict probable dysexecutive/psychiatric disorders in PM women. Conclusions: This is the first study supporting presence of specific epigenetic etiology associated with increased risk of developing comorbid dysexecutive and social anxiety symptoms in PM women. These findings could have implications for early intervention and risk estimate recommendations aimed at improving the outcomes for PM women and their families.

[1]  R. Eiges,et al.  FMR1 Epigenetic Silencing Commonly Occurs in Undifferentiated Fragile X-Affected Embryonic Stem Cells , 2014, Stem cell reports.

[2]  D. Loesch,et al.  Early detection of fragile X syndrome: applications of a novel approach for improved quantitative methylation analysis in venous blood and newborn blood spots. , 2014, Clinical chemistry.

[3]  Dalyir I. Pretto,et al.  CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size. , 2014, Human molecular genetics.

[4]  N. Gromak,et al.  R-loops Associated with Triplet Repeat Expansions Promote Gene Silencing in Friedreich Ataxia and Fragile X Syndrome , 2014, PLoS genetics.

[5]  F. Chédin,et al.  Transcription-Associated R-Loop Formation across the Human FMR1 CGG-Repeat Region , 2014, PLoS genetics.

[6]  M. Disney,et al.  Promoter-Bound Trinucleotide Repeat mRNA Drives Epigenetic Silencing in Fragile X Syndrome , 2014, Science.

[7]  P. Jin,et al.  Genome-wide alteration of 5-hydroxymethylcytosine in a mouse model of fragile X-associated tremor/ataxia syndrome. , 2014, Human molecular genetics.

[8]  J. Bradshaw,et al.  Impaired response inhibition is associated with self‐reported symptoms of depression, anxiety, and ADHD in female FMR1 premutation carriers , 2014, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[9]  Jonathan Cohen,et al.  Cognitive-motor interference during postural control indicates at-risk cerebellar profiles in females with the FMR1 premutation , 2013, Behavioural Brain Research.

[10]  C. Wahlestedt,et al.  Comprehensive analysis of the transcriptional landscape of the human FMR1 gene reveals two new long noncoding RNAs differentially expressed in Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome , 2013, Human Genetics.

[11]  Peter K. Todd,et al.  CGG Repeat-Associated Translation Mediates Neurodegeneration in Fragile X Tremor Ataxia Syndrome , 2013, Neuron.

[12]  J. Bradshaw,et al.  Neurobehavioural evidence for the involvement of the FMR1 gene in female carriers of fragile X syndrome , 2013, Neuroscience & Biobehavioral Reviews.

[13]  Tao Wang,et al.  Genome-wide DNA hydroxymethylation changes are associated with neurodevelopmental genes in the developing human cerebellum. , 2012, Human molecular genetics.

[14]  D. Loesch,et al.  Fragile X–related element 2 methylation analysis may provide a suitable option for inclusion of fragile X syndrome and/or sex chromosome aneuploidy into newborn screening: a technical validation study , 2012, Genetics in Medicine.

[15]  J. Greenberg,et al.  Prevalence of CGG expansions of the FMR1 gene in a US population‐based sample , 2012, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[16]  D. Loesch,et al.  Fragile X mental retardation 1 (FMR1) intron 1 methylation in blood predicts verbal cognitive impairment in female carriers of expanded FMR1 alleles: evidence from a pilot study. , 2012, Clinical chemistry.

[17]  R. Sandberg,et al.  CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing , 2011, Nature.

[18]  D. Loesch,et al.  FMR1 intron 1 methylation predicts FMRP expression in blood of female carriers of expanded FMR1 alleles. , 2011, The Journal of molecular diagnostics : JMD.

[19]  D. Mackinnon.  Integrating Mediators and Moderators in Research Design , 2011, Research on social work practice.

[20]  P. Hagerman,et al.  CGG-repeat length threshold for FMR1 RNA pathogenesis in a cellular model for FXTAS. , 2011, Human molecular genetics.

[21]  D. Loesch,et al.  Evidence for the toxicity of bidirectional transcripts and mitochondrial dysfunction in blood associated with small CGG expansions in the FMR1 gene in patients with parkinsonism , 2011, Genetics in Medicine.

[22]  E. Sekinger,et al.  An information-rich CGG repeat primed PCR that detects the full range of fragile X expanded alleles and minimizes the need for southern blot analysis. , 2010, The Journal of molecular diagnostics : JMD.

[23]  D. Loesch,et al.  Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio. , 2010, Human molecular genetics.

[24]  M. Tejada,et al.  Risk of cognitive impairment in female premutation carriers of fragile X premutation: Analysis by means of robust segmented linear regression models , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[25]  Jane E. Roberts,et al.  Mood and anxiety disorders in females with the FMR1 premutation , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[26]  M. Tejada,et al.  Analysis of the molecular parameters that could predict the risk of manifesting premature ovarian failure in female premutation carriers of fragile X syndrome , 2008, Menopause.

[27]  C. Goetz,et al.  FMR1 CGG repeat length predicts motor dysfunction in premutation carriers , 2008, Neurology.

[28]  Jeannie T. Lee,et al.  Evidence that homologous X-chromosome pairing requires transcription and Ctcf protein , 2007, Nature Genetics.

[29]  Eric J. Nestler,et al.  Epigenetic regulation in psychiatric disorders , 2007, Nature Reviews Neuroscience.

[30]  M. Eysenck,et al.  Anxiety and cognitive performance: attentional control theory. , 2007, Emotion.

[31]  I. Weaver,et al.  Epigenetic programming by maternal behavior , 2004, Nature Neuroscience.

[32]  S. Tapscott,et al.  CTCF-binding sites flank CTG/CAG repeats and form a methylation-sensitive insulator at the DM1 locus , 2001, Nature Genetics.

[33]  S. Sherman,et al.  Premature ovarian failure in the fragile X syndrome. , 2000, American journal of medical genetics.

[34]  A. Reiss,et al.  Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome. , 1999, American journal of medical genetics.

[35]  M. Leboyer,et al.  Genotype–phenotype relationship in female carriers of the premutation and full mutation of FMR-1 , 1998, Psychiatry Research.

[36]  B. Ramsahoye,et al.  DNA methylation in mouse embryonic stem cells and development , 2007, Cell and Tissue Research.

[37]  P. Lovibond,et al.  Manual for the Depression Anxiety Stress Scales. 2 , 1995 .

[38]  J. Angst,et al.  Social phobia. , 1995, European archives of psychiatry and clinical neuroscience.